Drug
LCL161 clinical trials
Also written LCL161.
- studies test it
- 10
- open now
- 0
- in phase 3
- 0
- first study started
- 2008
How studies write it
Studies that test it under each name
Name
Development codes
- LCL161
- 10
Studies by the year they started
10 studies that test it; most in 2013 (2)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 2 |
| 2016 | 2 |
| 2017 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 7
- Phase 2
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 7 · Other 3
Novartis Pharmaceuticals (6) · M.D. Anderson Cancer Center (1) · Mayo Clinic (1) · SCRI Development Innovations, LLC (1) · US Oncology Research (1)
Often tested with
Tested in the same studies.
Spartalizumab (2) · Paclitaxel (2) · Everolimus (1) · Panobinostat (1) · CXCR2 Antagonist QBM076 (1) · Siremadlin (1) · CJM-112 (1) · Cyclophosphamide (1)
Studies
Open first, then newest update. How each study uses LCL161 is read from its arms, and is right about nine times in ten.
Testing it · 10
- LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic MalignanciesTerminatedPhase 1SCRI Development Innovations, LLCNCT02649673Written as LCL161
- LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis MyelofibrosisCompletedPhase 2M.D. Anderson Cancer CenterNCT02098161Written as Smac Mimetic LCL161
- A Study of PDR001 in Combination With LCL161, Everolimus or PanobinostatCompletedPhase 1Novartis PharmaceuticalsNCT02890069Written as LCL161
- Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple MyelomaCompletedPhase 1Novartis PharmaceuticalsNCT03111992Written as LCL161
- A Study of LCL161 in Combination With Weekly Paclitaxel in Adult Patients With Advanced Solid TumorsCompletedPhase 1Novartis PharmaceuticalsNCT01240655Written as LCL161
- Safety and Tolerability of Oral LCL161 in Japanese Adult Patients With Advanced Solid TumorsCompletedPhase 1Novartis PharmaceuticalsNCT01968915Written as LCL161
- SMAC Mimetic LCL161 Alone or With Cyclophosphamide in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedPhase 2Mayo ClinicNCT01955434Written as Smac Mimetic LCL161
- A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast CancerCompletedPhase 2Novartis PharmaceuticalsNCT01617668Written as LCL161
- Phase I Trial of LCL161 and Gemcitabine Plus Nab-Paclitaxel in Metastatic Pancreatic CancerStatus unknownPhase 1US Oncology ResearchNCT01934634Written as LCL161
- Safety and Efficacy of LCL161 in Patients With Solid TumorsCompletedPhase 1Novartis PharmaceuticalsNCT01098838Written as LCL161
Codes
What other systems call LCL161 · ClinicalTrials.gg INT006121
- NCI Thesaurus C91079Smac Mimetic LCL161One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| NCI Thesaurus | C91079 | Smac Mimetic LCL161 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.